Physician profile
Laurel A Kubby
NPI 1427046291
$784.87
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2021: $116.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $263.16 | 2019-2021 | |
| Therapeuticsmd, INC. | $216.67 | 2019 | |
| Merck Sharp & Dohme LLC | $119.73 | 2019 | |
| Pfizer INC. | $45.85 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.96 | 2019 | |
| Millicent US INC | $19.09 | 2019 | |
| Minerva Surgical, INC | $17.02 | 2019 | |
| Allergan, INC. | $15.99 | 2019 | |
| Lupin INC. | $13.58 | 2019 | |
| Amgen INC. | $13.33 | 2019 | |
| Duchesnay USA Incorporated | $12.20 | 2019 | |
| Coopersurgical, INC. | $11.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Kubby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.